Breathe Well Live Well
Reuters |
FDA staff finds no new safety problems with Glaxo's asthma drug
Reuters (Reuters) – GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems while being tested to treat asthma, a preliminary review by U.S. Food and Drug Administration staff found. The review comes two … Ad Comm meeting approaches for expanded indication for Glaxo's COPD med … |
View full post on asthma – Google News
Reuters |
FDA staff finds no new safety problems with Glaxo's asthma drug
Business Insider (Reuters) – GlaxoSmithKline Plc's respiratory treatment for chronic breathing problems did not show any new safety problems in treating asthma, a preliminary review by U.S. Food and Drug Administration staff found. The review comes two days ahead of a … Ad Comm meeting approaches for expanded indication for Glaxo's COPD med … |
View full post on asthma – Google News
Conditions: Rhinitis; Rhinoconjunctivitis; Asthma
Interventions: Biological: DP/MG/14-1; Biological: DP/MG/14-2
Sponsor: Laboratorios Leti, S.L.
Recruiting – verified January 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: QGE031; Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Not yet recruiting – verified January 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Biological: Benralizumab; Biological: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified December 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Drug: Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler; Drug: Placebo inhalation powders via ELLIPTA inhaler; Drug: Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler; Drug: Placebo inhalation powder via ACCUHALER/DISKUS inhaler; Drug: Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler
Sponsor: GlaxoSmithKline
Not yet recruiting – verified November 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
|
AB Science: Web conference on masitinib in asthma – Safety and Efficacy Update
GlobeNewswire (press release) Paris, France, Nov. 25, 2014 (GLOBE NEWSWIRE) — AB Science SA (NYSE Euronext – FR0010557264 – AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), is hosting a web … |
View full post on asthma – Google News
Condition: Oral Corticosteroid Dependent Asthma
Interventions: Biological: Tralokinumab; Other: Placebo
Sponsor: AstraZeneca
Not yet recruiting – verified October 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Asthma
Interventions: Biological: Mepolizumab; Drug: Placebo; Drug: SOC
Sponsor: GlaxoSmithKline
Not yet recruiting – verified October 2014
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
WFMJ |
Halloween safety tips for kids with asthma
WFMJ Hayrides and haunted houses are exciting adventures that can lead to asthma flare-ups. Make sure children carry their quick-relief inhaler with them at all times so they can use it at the first sign of worsening symptoms. Children who've had breathing … |
View full post on asthma – Google News